Cambridge Cognition Holdings plc, (AIM: COG), announces the launch of CANTAB Insight, a new ground-breaking medical application which rapidly assesses an individual’s cognitive health and wellbeing to facilitate faster access to the most appropriate treatments and care.
With 1 in 4 adults experiencing a diagnosable mental health problem each year1 and the annual cost to global economies now exceeding $2.5 trillion2, there is a great need for expert cognitive measures to help identify and triage patients for early intervention and treatment.
Having reached a landmark 25,000 patient evaluations in the UK NHS with the Alzheimer’s triage tool CANTAB Mobile, the Company has developed CANTAB Insight for practitioners to perform in-depth neuropsychological evaluations with at risk patients on an iPad in just 20 minutes.
CANTAB Mobile identifies the initial signs of clinically relevant memory problems and CANTAB Insight now enables healthcare professionals to perform further investigation with at risk patients to detect underlying signs of common mental health problems such as depression, schizophrenia and dementia.
CANTAB Insight’s new touchscreen assessment has now gained CE marking approval for use as a Class II medical device and it will now be licensed into European public and occupational health markets through corporate partnerships as part of the Company’s ongoing strategy to provide leading neurotechnology products for healthcare services and pharmaceutical developers worldwide.
Director of Healthcare Innovation at Cambridge Cognition, Dr Jenny Barnett commented: “CANTAB Insight will empower users to accurately triage individuals, recommend efficacious interventions and promote better lifestyle management to improve cognitive health and wellbeing – leading to better outcomes for patients and their families.”
Chief Operating Officer, Dr Steven Powell added: “With CANTAB Insight now providing full cognitive health assessments alongside CANTAB Mobile, our healthcare technology business is in a strong position for geographic expansion in 2016.”
For further information visit www.CANTAB.com/insight
1 The Office for National Statistics Psychiatric Morbidity report, 2001.
2 World Health Organization. Global status report on non-communicable diseases, 2010.
With 1 in 4 adults experiencing a diagnosable mental health problem each year1 and the annual cost to global economies now exceeding $2.5 trillion2, there is a great need for expert cognitive measures to help identify and triage patients for early intervention and treatment.
Having reached a landmark 25,000 patient evaluations in the UK NHS with the Alzheimer’s triage tool CANTAB Mobile, the Company has developed CANTAB Insight for practitioners to perform in-depth neuropsychological evaluations with at risk patients on an iPad in just 20 minutes.
CANTAB Mobile identifies the initial signs of clinically relevant memory problems and CANTAB Insight now enables healthcare professionals to perform further investigation with at risk patients to detect underlying signs of common mental health problems such as depression, schizophrenia and dementia.
CANTAB Insight’s new touchscreen assessment has now gained CE marking approval for use as a Class II medical device and it will now be licensed into European public and occupational health markets through corporate partnerships as part of the Company’s ongoing strategy to provide leading neurotechnology products for healthcare services and pharmaceutical developers worldwide.
Director of Healthcare Innovation at Cambridge Cognition, Dr Jenny Barnett commented: “CANTAB Insight will empower users to accurately triage individuals, recommend efficacious interventions and promote better lifestyle management to improve cognitive health and wellbeing – leading to better outcomes for patients and their families.”
Chief Operating Officer, Dr Steven Powell added: “With CANTAB Insight now providing full cognitive health assessments alongside CANTAB Mobile, our healthcare technology business is in a strong position for geographic expansion in 2016.”
For further information visit www.CANTAB.com/insight
1 The Office for National Statistics Psychiatric Morbidity report, 2001.
2 World Health Organization. Global status report on non-communicable diseases, 2010.
